



Primary Care Reimbursement Service
Exit 5, M50, North Road, Finglas, Dublin 11, D11 XKF3
Tel: 01- 8647100

Mr. James Browne, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

9th January, 2019

PQ: 47997/18

To ask the Minister for Health the number of drugs considered by the rare disease technology review committee; the names of the drugs; and if he will make a statement on the matter. -James Browne.

Dear Deputy Browne,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 47997/18), which you submitted to the Minister for Health for response.

The Rare Diseases Technology Review Committee (RDTRC) was established in 2018 and to date has been asked by the HSE Drugs Group to review two orphan drugs: sapropterin and nusinersen.

The first drug reviewed by the RDTRC was sapropterin (Kuvan®).

The second drug reviewed by RDTRC was nusinersen (Spinraza®) for spinal muscular atrophy (SMA).

Yours sincerely,

Kieran Healy
Primary Care Reimbursement Service